tiprankstipranks
Trending News
More News >
Noronex Ltd. (AU:NRX)
ASX:NRX
Australian Market

Noronex Ltd. (NRX) AI Stock Analysis

Compare
6 Followers

Top Page

AU:NRX

Noronex Ltd.

(Sydney:NRX)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
AU$0.02
▲(70.00% Upside)
The score is primarily constrained by weak financial performance—ongoing losses, worsening cash burn, and shrinking equity—despite the benefit of having no debt. Technicals add modest support with price slightly above key averages and mildly positive momentum, while valuation remains challenged because the company is loss-making and offers no dividend yield.
Positive Factors
Zero debt / conservative financing
A zero-debt capital structure materially lowers refinancing and interest-rate risk, preserving cash flow for operations or growth. Over a multi-month horizon this improves financial optionality for funding, permitting the company to endure revenue seasonality or pursue strategic investments without immediate debt pressure.
Top-line growth trajectory
Sustained revenue growth from a low base signals successful market traction and the potential to leverage fixed costs. If this scaling continues, it can drive operating leverage, narrow negative margins and reduce reliance on external funding, supporting a path toward durable profitability over coming quarters.
ASX listing provides capital access
Being listed on the ASX gives the company ongoing access to public equity markets and broader investor pools, an important structural advantage given current cash burn. This listing status enhances long-term funding options and liquidity compared with private peers, aiding future capital raises if operational momentum persists.
Negative Factors
Worsening operating cash burn
Deepening negative operating cash flow indicates the business is not yet self-funding and faces increasing reliance on external capital. Persisting cash burn over several quarters raises financing risk, heightens dilution potential, and constrains the ability to invest in growth or respond to adverse industry developments.
Large and expanding net losses
Very large, widening losses and severely negative margins reflect structural unprofitability that erodes shareholder capital. Without clear margin improvement or cost structure changes, the firm will struggle to generate sustainable returns, making long-term viability contingent on significant operational turnaround or scale.
Shrinking equity base weakens capitalization
A rapid decline in shareholders' equity reduces the balance sheet buffer against losses and limits financial flexibility. This weaker capitalization increases the urgency of external funding, raises dilution risk for existing shareholders, and can impair the company’s ability to execute longer-term strategic initiatives without costly capital raises.

Noronex Ltd. (NRX) vs. iShares MSCI Australia ETF (EWA)

Noronex Ltd. Business Overview & Revenue Model

Company DescriptionNoronex Limited operates as a mineral exploration company. The company primarily explores for base and precious metals, as well as copper deposits. It focuses on Witvlei project comprising two prospecting licences covering an area of approximately 390 square kilometers located in Kalahari Copper Belt, Namibia. The company was formerly known as Lustrum Minerals Limited and changed its name to Noronex Limited in November 2020. Noronex Limited was incorporated in 2015 and is based in Subiaco, Australia.
How the Company Makes MoneyNoronex Ltd. makes money primarily through the exploration and potential development of mineral resources. The company generates revenue by advancing its exploration projects to a stage where they can attract larger mining companies or investors, who may purchase the rights to develop the site or enter into joint ventures. Noronex might also earn income from selling exploration data, securing government grants, or through strategic partnerships with other companies in the mining sector. Additionally, in the long term, if any of their projects reach the production stage, they could earn revenue from the sale of extracted minerals.

Noronex Ltd. Financial Statement Overview

Summary
Revenue growth is strong off a low base, but profitability remains very weak with a widening net loss and deeply negative margins. Cash flow is a major risk with worsening operating cash burn and negative free cash flow, implying ongoing funding dependence. The main offset is zero debt, but the equity base has shrunk meaningfully, reducing financial flexibility.
Income Statement
18
Very Negative
Revenue has begun to scale (up ~59% in FY2025 vs FY2024), but profitability remains very weak. FY2025 net loss widened to about -$3.1M with a deeply negative net margin (around -850%), and operating losses persisted (negative EBIT/EBITDA). While the top-line trajectory is improving from a low base, the company is still firmly in a loss-making phase with no clear margin stabilization yet.
Balance Sheet
52
Neutral
The balance sheet is conservatively financed with zero debt across the periods provided, reducing refinancing and interest-rate risk. However, the equity base has declined meaningfully (about $3.0M in FY2024 to ~$1.0M in FY2025) and returns on equity are sharply negative (FY2025 ROE roughly -3.29x), reflecting ongoing losses and erosion of shareholder capital. Overall: low leverage, but weakening capitalization.
Cash Flow
16
Very Negative
Cash generation is a key concern: operating cash flow and free cash flow are consistently negative (FY2025 operating cash flow about -$3.7M, worse than FY2024’s roughly -$2.4M). Cash burn is not being offset by earnings (both are negative), and the overall trend suggests funding dependence remains high until operating spending is brought under control or revenues scale materially.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue368.16K368.16K40.68K0.000.000.00
Gross Profit368.16K368.16K40.68K0.000.000.00
EBITDA-1.08M-1.08M-2.52M36.40K148.07K25.73K
Net Income-3.13M-3.13M-2.51M-3.35M-5.55M-2.15M
Balance Sheet
Total Assets2.20M2.20M3.81M3.32M5.05M5.72M
Cash, Cash Equivalents and Short-Term Investments1.01M1.01M913.58K393.75K2.11M3.01M
Total Debt0.000.000.000.000.000.00
Total Liabilities1.22M1.22M754.42K424.52K468.48K259.97K
Stockholders Equity951.15K951.15K3.02M2.85M4.36M5.11M
Cash Flow
Free Cash Flow-3.68M-3.68M-2.36M-3.12M-5.36M-2.06M
Operating Cash Flow-3.68M-3.68M-2.36M-3.12M-5.28M-1.80M
Investing Cash Flow-42.61K-42.61K412.06K0.00-80.00K-703.93K
Financing Cash Flow3.78M3.78M2.47M1.42M4.46M4.02M

Noronex Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.01
Price Trends
50DMA
0.02
Positive
100DMA
0.02
Positive
200DMA
0.02
Positive
Market Momentum
MACD
<0.01
Negative
RSI
55.64
Neutral
STOCH
200.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NRX, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NRX.

Noronex Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
50
Neutral
AU$278.07M-3.63
50
Neutral
AU$6.17M-1.14-25.55%-34.62%
49
Neutral
€251.44M-32.61-73.21%-11.29%
49
Neutral
AU$203.86M-1.38-57.00%-1789.13%
48
Neutral
AU$9.37M-2.46-157.73%6.15%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:NRX
Noronex Ltd.
0.02
0.00
0.00%
AU:CYM
Cyprium Metals Limited
0.57
0.32
128.74%
AU:CVV
Caravel Minerals Limited
0.45
0.26
130.77%
AU:REC
Recharge Metals Limited
0.02
<0.01
20.00%
AU:AR1
Austral Resources Australia Limited
0.12
-0.04
-25.00%

Noronex Ltd. Corporate Events

Noronex Launches Maiden Drilling at Etango North Uranium Project in Namibia
Jan 27, 2026

Noronex has commenced its maiden reverse circulation drilling program at the Etango North Uranium Project in Namibia, marking the company’s first uranium-focused drilling campaign in the country. The program, carried out by Namibian contractor Ferrodrill, will test multiple high-priority subsurface uranium targets defined by ground spectrometry, remote sensing, and field mapping, including U/Th anomalies and interpreted extensions of alaskite-hosted mineralisation in structurally favourable settings typical of the central Namibian hard-rock uranium district. Success at Etango North could strengthen Noronex’s position in a world-class uranium province and complement its ongoing copper exploration activities in Namibia and Botswana, potentially broadening its resource base and strategic appeal to investors exposed to the energy-transition metals space.

The most recent analyst rating on (AU:NRX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Noronex Ltd. stock, see the AU:NRX Stock Forecast page.

Noronex Appoints Drilling Contractor for Maiden Program at Etango North Uranium Project
Jan 22, 2026

Noronex has appointed a drilling contractor for its maiden reverse-circulation drilling program at the Etango North Uranium Project in Namibia, with work expected to begin shortly. The campaign will test multiple high-priority uranium and thorium anomalies and alaskite extensions defined by a 2025 ground spectrometry survey, supported by recent remote sensing and lithostratigraphic interpretation that have refined the geological model and highlighted favourable domal and structural settings for alaskite-hosted uranium. Etango North, where Noronex can earn up to an 80% interest, lies immediately along strike from Bannerman’s large Etango development and close to the Rossing and Husab mines, underscoring the project’s potential significance. Management describes the program as a key milestone that could deliver a greenfields uranium discovery while the company continues to progress its broader copper exploration portfolio in Namibia and Botswana, potentially enhancing its growth profile in the African energy metals sector.

The most recent analyst rating on (AU:NRX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Noronex Ltd. stock, see the AU:NRX Stock Forecast page.

Noronex Extends Copper-Silver Mineralisation at Namibia’s Powerline Project
Jan 21, 2026

Noronex has reported further encouraging assay results from its ongoing 7,000m RC drilling program at the Powerline Copper Project in Eastern Namibia, where approximately 5,300m across 23 holes have now been completed at the Steenbok, Qembo and Zambinda domes. New copper-silver intercepts at the Qembo and Steenbok targets, including up to 4m at 0.58% copper and 69g/t silver and 9m at 0.24% copper and 29g/t silver, confirm mineralisation along the key D’Kar-NPF contact and demonstrate continuity with earlier results, strengthening the project’s structural and stratigraphic model. With drilling now shifted east to test the Zambinda Dome and all work funded by South32 under the earn-in arrangement, the results validate Noronex’s targeting strategy and enhance the exploration potential of its ground in the Kalahari Copper Belt amid strong copper and silver prices.

The most recent analyst rating on (AU:NRX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Noronex Ltd. stock, see the AU:NRX Stock Forecast page.

Noronex Advances Kalahari Drilling, Sells Witvlei Asset and Funds Etango Uranium Program
Jan 20, 2026

Noronex reported a highly active December 2025 quarter marked by major reverse circulation drill programs at its Powerline Copper Project in Namibia and under a new earn-in agreement with South32 at Cgae Cgae in Botswana, where early results at Powerline, including a 9m intercept grading 0.45% copper and 43g/t silver, validate its geological targeting strategy. The company also moved to streamline its portfolio and strengthen its balance sheet by agreeing to sell its non-core Witvlei asset for A$4.5 million in staged payments and completing a A$750,000 strategic placement, with proceeds earmarked to fund a maiden drilling campaign at the Etango North Uranium Project scheduled to start in February 2026, underpinning a broader push to unlock value from its extensive Kalahari Copper Belt and Namibian uranium holdings.

The most recent analyst rating on (AU:NRX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Noronex Ltd. stock, see the AU:NRX Stock Forecast page.

Noronex Advances Sale of Witvlei Project to Focus on Core Copper Assets
Dec 2, 2025

Noronex Limited has announced the progression of the sale of its non-core Witvlei Project in Namibia, receiving a non-refundable deposit of A$200,000 from Joint Era Mining Co., Limited. This transaction, valued at A$4.5 million, allows Noronex to focus on its extensive copper portfolio, including projects in collaboration with South32. The sale is part of Noronex’s strategy to concentrate on its core assets, potentially enhancing its industry positioning and resource management.

Noronex Limited Updates Director’s Interest with New Option Issuance
Nov 28, 2025

Noronex Limited has announced a change in the director’s interest notice, specifically regarding Robert Klug’s holdings. Mr. Klug has acquired 5,000,000 unquoted options exercisable at $0.025 each on or before October 1, 2027, increasing his total holdings to include these new options. This change reflects the issuance of incentive options as part of a previously noted meeting, potentially impacting the company’s leadership incentives and aligning director interests with company performance.

Noronex Director Acquires Additional Options
Nov 28, 2025

Noronex Limited has announced a change in the interests of its director, Piers Lewis, involving the acquisition of 5,000,000 unquoted options exercisable at $0.025 each on or before October 1, 2027. This issuance of incentive options, as referenced in the Notice of Meeting dated October 10, 2025, reflects a strategic move to potentially enhance the director’s stake in the company, which could influence the company’s governance and decision-making processes.

Noronex Director Acquires 5 Million Unquoted Options
Nov 28, 2025

Noronex Limited has announced a change in the interests of its director, David Prentice, involving the acquisition of 5,000,000 unquoted options. These options are exercisable at $0.025 each and are set to expire on 1 October 2027. This change reflects an issuance of incentive options as per the Notice of Meeting dated 10 October 2025, indicating a strategic move to align the director’s interests with the company’s long-term goals.

Noronex Limited Issues New Shares Under Regulatory Exemption
Nov 28, 2025

Noronex Limited has announced the issuance of 5,333,333 fully paid ordinary shares, which are exempt from the on-sale restrictions under the Corporations Act 2001. This move is part of the company’s compliance with regulatory requirements, ensuring transparency and maintaining its obligations under the Act. The announcement indicates that there is no undisclosed information that would impact investors’ assessments of the company’s financial position or the rights attached to the shares.

Noronex Ltd. Issues 15 Million Unquoted Options
Nov 28, 2025

Noronex Limited has announced the issuance of 15 million unquoted options, set to expire on October 1, 2027, at an exercise price of $0.025. This issuance, part of an employee incentive scheme, is intended to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests.

Noronex Limited Issues New Securities Under Employee Incentive Scheme
Nov 28, 2025

Noronex Limited has announced the issuance of 3,000,000 performance rights and 3,000,000 options as part of an employee incentive scheme. This move is aimed at motivating and retaining key personnel, potentially strengthening the company’s operational capabilities and aligning employee interests with shareholder objectives.

Noronex Limited Issues New Shares for PR Services
Nov 28, 2025

Noronex Limited has announced the issuance of 500,000 ordinary fully paid shares on November 28, 2025, for investor relations and public relations services. This move is part of their strategic efforts to enhance market visibility and engagement, potentially impacting their stakeholder relationships and market positioning.

Noronex Limited Issues 500,000 Shares for IR/PR Services
Nov 28, 2025

Noronex Limited has announced the issuance of 500,000 ordinary fully paid shares on November 28, 2025, as part of an agreement for IR/PR services. This move signifies a strategic effort by Noronex to enhance its investor relations and public relations capabilities, potentially impacting its market presence and stakeholder engagement.

Noronex Limited Issues 3 Million New Securities for ASX Quotation
Nov 28, 2025

Noronex Limited has announced the issuance of 3,000,000 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code NRX. This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence, offering stakeholders an opportunity to invest in its growth trajectory.

Noronex Unveils Promising Copper-Silver Drilling Results in Namibia
Nov 25, 2025

Noronex Limited has announced promising initial assay results from its ongoing 7,000-meter Reverse Circulation drilling program at the Powerline Copper Project in Namibia. The drilling, funded through an agreement with South32, has identified a significant zone of copper-silver mineralization, validating the company’s geological model and exploration strategy. The project aims to explore the D’Kar-NPF contact horizon, with further drilling planned to assess the potential extensions of the mineralized zone. These findings are expected to enhance Noronex’s position in the copper mining sector and provide valuable insights for future exploration efforts.

Noronex Limited Announces Proposed Issue of 20 Million Unlisted Options
Nov 24, 2025

Noronex Limited has announced a proposed issue of 20,000,000 unlisted options, exercisable at $0.024 and expiring 24 months from the issue date. This move is part of a placement or other type of issue, with the proposed issue date set for December 24, 2025. The announcement may impact the company’s financial structure and market positioning by potentially increasing its capital base and providing additional resources for its operations.

Noronex Divests Witvlei Project to Focus on Core Assets
Nov 23, 2025

Noronex Limited has announced the sale of its non-core Witvlei Project in Namibia to Joint Era Mining Co., Limited for A$4.5 million. This strategic divestment allows Noronex to streamline its operations and focus on its core projects in the Kalahari Copper Belt. The proceeds from the sale will be used to strengthen the company’s balance sheet and fund exploration at the Etango North Uranium Project, positioning Noronex for future growth and development opportunities.

Noronex Ltd. Updates Constitution to Enhance Governance
Nov 10, 2025

Noronex Ltd. has adopted a new constitution as of November 30, 2022, with amendments made on November 10, 2025. The updated constitution outlines the company’s governance structure, including share capital, rights, and securities holding, which are crucial for its operational and strategic direction.

Noronex Limited Secures Shareholder Approval for Key Resolutions at AGM
Nov 10, 2025

Noronex Limited announced the successful passing of all resolutions at its Annual General Meeting, including the adoption of the remuneration report, re-election of David Prentice, and approval of various incentive options and mandates. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives, potentially impacting its operational efficiency and market competitiveness.

Noronex Expands Exploration Efforts in Namibia and Botswana
Oct 30, 2025

Noronex Limited has announced significant progress in its exploration activities, particularly in Namibia and Botswana. The company has reported promising copper intercepts from its Fiesta Copper Project in Namibia and has initiated a 7,000m RC drilling program at the Powerline Project. Additionally, Noronex has expanded its strategic alliance with South32 to include new tenements in Botswana, with a commitment of up to A$5 million over five years. The company has also identified new uranium targets at the Etango North Uranium Project and completed a $750,000 placement to support ongoing exploration efforts. These developments are expected to strengthen Noronex’s position in the mining sector and potentially lead to new discoveries.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 28, 2026